These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Alpha toxoid of Clostridium perfringens. I. Purification and toxoiding of alpha toxin of C. perfringens. Ito A Jpn J Med Sci Biol; 1968 Dec; 21(6):379-91. PubMed ID: 4306752 [No Abstract] [Full Text] [Related]
25. Two molecular forms of Clostridium perfringens alpha-toxin associated with lethal, hemolytic and enzymatic activities. Sugahara T; Osaka A Jpn J Med Sci Biol; 1970 Feb; 23(1):61-6. PubMed ID: 4317541 [No Abstract] [Full Text] [Related]
26. Isolation and characterization of a protease from Clostridium botulinum type B. Dasgupta BR; Sugiyama H Biochim Biophys Acta; 1972 Jun; 268(3):719-29. PubMed ID: 4556539 [No Abstract] [Full Text] [Related]
27. Significance of 12S toxin of Clostridium botulinum type E. Kitamura M; Sakaguchi S; Sakaguchi G J Bacteriol; 1969 Jun; 98(3):1173-8. PubMed ID: 4977983 [TBL] [Abstract][Full Text] [Related]
28. Partial purification and characterization of a lethal protein from Tripneustes gratilla. Fleming WJ; Howden ME Toxicon; 1974 Aug; 12(4):447-8. PubMed ID: 4439418 [No Abstract] [Full Text] [Related]
29. Purification of Clostridium perfringens type C theta toxin. Hauschild AH; Lecroisey A; Alouf JE Can J Microbiol; 1973 Aug; 19(8):881-5. PubMed ID: 4356555 [No Abstract] [Full Text] [Related]
30. [A study of botulin toxins and anatoxins by the gel filtration method. II. Separation of native type A botulin toxins by filtration through Sephadex G-200 gel]. Freĭman VB; Golshmid VK; Mikhaĭlova IM Zh Mikrobiol Epidemiol Immunobiol; 1967 Aug; 44(8):106-9. PubMed ID: 4891690 [No Abstract] [Full Text] [Related]
31. Toxicity of bacterial sphingomyelinases D. Soucek A; Soucková A J Hyg Epidemiol Microbiol Immunol; 1974; 18(3):327-35. PubMed ID: 4213711 [No Abstract] [Full Text] [Related]
32. Antigenicites of fragments of Clostridium botulinum type B derivative toxin. Kozaki S; Sakaguchi G Infect Immun; 1975 May; 11(5):932-6. PubMed ID: 804447 [TBL] [Abstract][Full Text] [Related]
33. Behaviour of toxin released from the cells of Clostridium botulinum type E. Kitamura M Biochem Biophys Res Commun; 1970 Aug; 40(4):925-31. PubMed ID: 4993018 [No Abstract] [Full Text] [Related]
34. Dissociation studies on the toxin of Clostridium botulinum type B. Mitchell B; Gerwing J Biochim Biophys Acta; 1969 May; 181(1):336-8. PubMed ID: 4893322 [No Abstract] [Full Text] [Related]
35. [Obtaining highly purified preparations of Cl. histolyticum lethal factor]. Shemanova GF; Vlasova EV; Shamraeva SA Vopr Med Khim; 1968; 14(6):632-5. PubMed ID: 4308707 [No Abstract] [Full Text] [Related]
36. Molecular construction of Clostridium botulinum type F progenitor toxin. Ohishi I; Sakaguchi G Appl Microbiol; 1975 Apr; 29(4):444-7. PubMed ID: 235882 [TBL] [Abstract][Full Text] [Related]
37. Dissociation of Clostridium botulinum type-E-toxin. Kitamura M; Sakaguchi S; Sakaguchi G Biochem Biophys Res Commun; 1967 Dec; 29(6):892-7. PubMed ID: 4965663 [No Abstract] [Full Text] [Related]
38. [Study of botulin toxin type F by means of filtration through Sephadex gel]. Golshmid VK; Mikhaĭlova IM Zh Mikrobiol Epidemiol Immunobiol; 1967 Jan; 44(1):46-9. PubMed ID: 4881675 [No Abstract] [Full Text] [Related]
39. Studies of an acidic cardiotoxin isolated from the venom of Mojave rattlesnake (Crotalus scutulatus). Bieber AL; Tu T; Tu AT Biochim Biophys Acta; 1975 Jul; 400(1):178-88. PubMed ID: 238654 [TBL] [Abstract][Full Text] [Related]